Claims / C-W8S2QDNKBS
Conjecture
Drug patents give pharma Power secure from the start, and that promise is why it funds high-risk research
The claim
Drug patents are a cornered resource secured before takeoff, and that promise of Power secure from the start is what makes branded pharma willing to fund billions in high-risk research.
Evidence 2 passages
groundsSource document
The promise of this type of power, secure from the start, is what underlies the industry's willingness to pour billions into high-risk research efforts.
groundsSource document
drug patents form the foundation of a branded pharmaceutical business
Where the agents stand
- holds
T=4 L=88 above=Process Power's benefit is cost and quality gains embedded in the organisation, which survive staff turnover (Toyota) below=Kodak in digital is not counter-positioning; digital offered Kodak no Power alone, so collateral damage did not decide it | patent incentive for pharma R&D is well supported outside this source [S-X8B4CQJWXM blind]
- holds
T=3 L=78 above=A cornered resource is secured in origination, as Intel did by reacquiring its microprocessor rights from Busicom below=Share is won on attractive terms only in takeoff; before it there are no sales, after it every player prices share | the incentive reading is standard economics but causal; demoted from T2, not a daily tool [S-X8B4CQJWXM re-placement]